The board of directors of Brii Biosciences Limited announced that Dr. Axel Bouchon tendered his resignation letter to resign as a non-executive Director with effect from September 30, 2022 in order to devote more time to his other commitments, including as the chief executive officer of a start-up company focusing on anti-depression. Following the resignation of Dr. Bouchon as a non-executive Director, he has also ceased to be a member of the strategy committee of the Board with effect from September 30, 2022. The Board announced that Dr. Taiyin Yang has been appointed as an independent non-executive Director with effect from September 1, 2022.

Following the appointment of Dr. Yang as an independent non-executive Director, she has also been appointed as a co-chairlady of the audit and risk committee of the Board (formerly known as the audit committee of the Board) (the "Audit and Risk Committee"), alongside with Ms. Grace Hui Tang, a co-chairlady of the Audit and Risk Committee, with effect from September 1, 2022. The biographical details of Dr. Yang are set out below: Dr. Yang, aged 69, has been appointed as an independent non-executive Director with such appointment to take effect from September 1, 2022. She has more than four decades of experience in developing and manufacturing medicines in several therapeutic categories.

Dr. Yang has been serving as a director of the board and a member of the audit committee of Kodiak Sciences Inc., a biopharmaceutical company listed on NASDAQ Stock Exchange in the United States (stock code: KOD), since December 2019. She has been serving as a director of the board and a member of the nominating and governance committee of Kronos Bio Inc., a biopharmaceutical company listed on NASDAQ Stock Exchange in the United States (stock code: KRON), since March 2021 and a member of its audit committee since August 2022, respectively. She has been serving as a member of the expert scientific advisory committee of Medicines for Malaria Venture, a non-profit research and development organization, since March 2020.

She has been serving as a member of the scientific advisory board of Sionna Therapeutics since August 2022. Dr. Yang held several positions in Gilead Sciences Inc. ("Gilead"), a biopharmaceutical company listed on NASDAQ Stock Exchange in the United States (stock code: GILD), from March 1993 to July 2022, including director of analytical chemistry and senior vice president of pharmaceutical development and manufacturing. Her last position at Gilead was executive vice president of pharmaceutical development and manufacturing, during which she was responsible for development and manufacturing for Gilead ' s small molecules, biologics and antibody-drug conjugates in development programs and commercial products.

She directed operations of process, device and formulation development, manufacturing, packaging, analytical operations, laboratory information systems and data science, quality assurance, regulatory affairs, chemistry, manufacturing and controls processes program management, product distribution, supply chain management and site operations including production, quality control, technical services, facility, engineering and environment, health and safety. Under her leadership, Gilead developed the world's first human immunodeficiency virus single tablet regimen in 2006 and advanced numerous compounds from early-stage development to market, reaching millions of people around the world. During her tenure at Gilead, she also served as the executive sponsor for Gilead Asian Interest Network, an employee resource group established in April 2018, to promote, support and encourage inclusion and diversity.

Before that, she held various positions in Syntex Corporation from January 1980 to March 1993, including staff researcher, department head of methods development and director of chemical analysis, supporting drug development. Dr. Yang has been admitted as a fellow of the American Institute for Medical and Biological Engineering in March 2021 and was elected as a member of the National Academy of Engineering in February 2022. Dr. Yang obtained a Bachelor of Science Degree in Chemistry from the National Taiwan University in Taiwan, the People's Republic of China in June 1974, and a Ph.D. in Organic Chemistry from University of Southern California in the United States in January 1980.

The Board announced the following change in composition of the Board committees: Following the resignation of Dr. Bouchon as a non-executive Director, he has also ceased to be a member of the Strategy Committee with effect from September 30, 2022; Following the appointment of Dr. Yang as an independent non-executive Director, she has also been appointed as a co-chairlady of the Audit and Risk Committee, alongside with Ms. Grace Hui Tang, a co-chairlady of the Audit and Risk Committee, with effect from September 1, 2022; Mr. Gregg Huber Alton, an independent non-executive Director, has been appointed as the chairman of the nomination committee of the Board (the "Nomination Committee") with effect from September 1, 2022; Dr. Zhi Hong, an executive Director and the chairman of the Board, has ceased to be the chairman of the Nomination Committee and will remain as a member of the Nomination Committee with effect from September 1, 2022; Dr. Martin J Murphy Jr, an independent non-executive Director, has ceased to be a member of the Audit and Risk Committee with effect from September 1, 2022; and Mr. Yiu Wa Alec Tsui, an independent non-executive Director, has ceased to be a member of the Nomination Committee with effect from September 1, 2022.